Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$7.59 -0.8%	$8.01	$3.76 ▼ $46.80	$46.77M	2.77	68,529 shs	37,062 shs
CSCI COSCIENS Biopharma	$3.48 -2.4%	$3.66	$1.96 ▼ $6.58	$11.01M	0.91	3,888 shs	1,491 shs
IPSC Century Therapeutics	$0.55 +3.2%	$0.58	$0.34 ▼ $2.05	$45.94M	1.78	958,757 shs	1.13 million shs
OSTX OS Therapies	$2.15 +14.4%	$1.78	$1.12 ▼ $7.00	$60.41M	N/A	731,759 shs	950,662 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-0.78%	-6.64%	-10.71%	+29.97%	-38.42%
CSCI COSCIENS Biopharma	-0.69%	+1.02%	+1.16%	-3.44%	+347,599,900.00%
IPSC Century Therapeutics	+3.15%	+3.93%	-4.91%	-1.79%	-64.74%
OSTX OS Therapies	+14.36%	+22.86%	+36.08%	+31.10%	-33.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.457 of 5 stars	3.5	4.0	0.0	4.8	2.6	1.7	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	3.1045 of 5 stars	3.5	4.0	0.0	0.0	2.7	1.7	0.6
OSTX OS Therapies	2.3101 of 5 stars	3.7	0.0	0.0	0.0	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	822.27% Upside
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
IPSC Century Therapeutics	3.00	Buy	$3.75	581.82% Upside
OSTX OS Therapies	3.40	Buy	$18.00	737.21% Upside

Current Analyst Ratings Breakdown

Latest CSCI, ALGS, IPSC, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.94M	11.77	N/A	N/A	$16.66 per share	0.46
CSCI COSCIENS Biopharma	$9.59M	1.14	N/A	N/A	$3.49 per share	1.00
IPSC Century Therapeutics	$6.59M	7.19	N/A	N/A	$1.90 per share	0.29
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	N/A
CSCI COSCIENS Biopharma	-$15.31M	-$5.80	N/A	∞	N/A	-194.50%	-101.01%	-43.90%	N/A
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Latest CSCI, ALGS, IPSC, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	N/A
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	-$0.38	N/A	-$0.38	N/A	N/A
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
CSCI COSCIENS Biopharma	N/A	2.88	2.54
IPSC Century Therapeutics	N/A	11.70	11.70
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
CSCI COSCIENS Biopharma	0.73%
IPSC Century Therapeutics	50.20%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
CSCI COSCIENS Biopharma	0.10%
IPSC Century Therapeutics	5.00%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	5.82 million	No Data
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

CSCI, ALGS, IPSC, and OSTX Headlines

Recent News About These Companies

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14 at 5:44 PM | newsfilecorp.comN

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

August 9, 2025 | finance.yahoo.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 7, 2025 | newsfilecorp.comN

OS Therapies files to sell 3.76M shares of common stock for holders

August 6, 2025 | msn.com

OS Therapies Inc News (OSTX) - Investing.com

July 18, 2025 | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

June 30, 2025 | businesswire.com

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24, 2025 | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025 | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, ALGS, IPSC, and OSTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$7.59 -0.06 (-0.78%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.83 +0.24 (+3.16%)

As of 08/14/2025 07:53 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

COSCIENS Biopharma NASDAQ:CSCI

$3.48 -0.08 (-2.36%)

Closing price 08/14/2025 03:41 PM Eastern

Extended Trading

$3.81 +0.33 (+9.61%)

As of 06:01 AM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Century Therapeutics NASDAQ:IPSC

$0.55 +0.02 (+3.15%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.55 +0.00 (+0.55%)

As of 04:36 AM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

OS Therapies NYSE:OSTX

$2.15 +0.27 (+14.36%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.16 +0.02 (+0.70%)

As of 04:53 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time